US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

25.12

+0.35181.42%

Volume:36.25K

Turnover:915.52K

Market Cap:58.28M

PE:- -

High:25.49

Open:24.86

Low:24.74

Close:24.77

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:0.86

T/O Rate:1.56%

Dividend:1.70

Dividend Rate:6.78%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year

THOMSON REUTERS

Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4

THOMSON REUTERS

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS

Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings

THOMSON REUTERS

Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year

THOMSON REUTERS

Aureka launches placement and share purchase plan to fund mine expansion and exploration

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

BioAge Labs doses first patient in QUELL-DME study

Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

NRx Pharma to Present at Moody Capital Solutions Disruptive Growth & Life Sciences Conference

FBR raises A$4m to accelerate DST-powered robotics rollout

Mizuho survey shows no consensus into Alkermes ADHD data

Right Resources shareholders back director placements and capital raising

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Compass Pathways Grants Inducement Equity Awards Covering 414,100 Shares to New Hires

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/PSIL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":25.12,"timestamp":1789416000000,"preClose":24.7682,"halted":0,"volume":36246,"delay":0,"changeRate":0.014203696675575972,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Pre-Mkt","change":0.3518,"latestTime":"09-15 05:43:45 EDT","open":24.86,"high":25.4912,"low":24.7417,"amount":915515.06025,"amplitude":0.030261,"askPrice":25.4,"askSize":3,"bidPrice":24,"bidSize":14,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.067799,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.12,"preClose":25.12,"latestTime":"19:30 EDT","volume":167,"amount":4194.275,"timestamp":1789428602004,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8625564020291175,"impliedVol":0.3109,"impliedVolPercentile":0.428},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8625564020291175,"shares":2319976,"dividePrice":1.7031,"high":25.4912,"amplitude":0.030261,"preClose":24.7682,"low":24.7417,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":25.12,"committee":0.647059,"eps":0,"divideRate":0.067799,"volume":36246,"delay":0,"ttmEps":0,"open":24.86,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.86,"twentyDayClose":25.2736,"sixtyDayClose":19.8284},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666554185","title":"Disc Medicine presents initial results from RESTORE phase 2 trial in PV patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554185?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:05","pubTimestamp":1788998708,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) “presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera. The dat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/disc-medicine-presents-initial-results-from-restore-phase-2-trial-in-pv-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","BK4139","LU0053671581.USD","IRON","DISC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535291","title":"U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535291","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535291?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:24","pubTimestamp":1788960267,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte SoftwareSeptember 9 (Reuters)-The main U.S. stock indexes were on course to open lower on Wednesday, when oil prices surged past the market-sensitive $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL6N4510Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIG","LU0080751232.USD","LU2023250504.SGD","LFST","LU0211326839.USD","LU2317271919.USD","LU2462157665.USD","IE000KEQY171.SGD","LU0174119429.USD","IE0003U64NQ7.SGD","SG9999015986.USD","LU0444973449.USD","LU0792757196.USD","LU0345774391.USD","LU1280957306.USD","LU2097829019.USD","TTAN","LU0029864427.USD","LU0345770308.USD","BK4559","SG9999014559.SGD","LU0265550946.USD","LU2357627491.SGD","FBY","LU2403377893.USD","LU2746668461.USD","METW","SG9999002224.SGD","COP","IE00BFMHRM44.USD","LU1868836757.USD","LU1301847155.USD","HK0000304797.USD","LU1917777945.USD","IE00B2Q91V27.USD","LU0368265418.SGD","LU0957808578.USD","LU0353189680.USD","LU2720916845.USD","LU0130517989.USD","LU0133085943.USD","ASO","LU1046421795.USD","LU1261432733.SGD","IE0009G5SDU7.USD","DOW","LU0957791311.USD","META","LU0096364046.USD","LU1121112475.USD","LU2272731782.SGD","LU0354030511.USD","LU0823421333.USD","CMPS","LU0345780950.USD","BK4592","LU1564329115.USD","LU1732799900.SGD","IE00B19Z3581.USD","PSIL","SG9999014906.USD","LU1868836591.USD","BK4212","BK4600","LU0211327993.USD","IE00BKVL7J92.USD","LU0943347566.SGD","IE00BJJMRX11.SGD","LU1267930573.SGD","LU0795875086.SGD","LU0256331488.USD","LU1861220207.SGD","SG9999002521.SGD","LU0127658192.USD","LU0210533765.USD","LU2129689605.HKD","METD","FMED","LU1496350171.SGD","LU1551013425.SGD","IE000BZT7R73.USD","IE00B3CCJ963.GBP","LU2404859741.USD","BK4543","LU1043141123.HKD","LU2326559502.SGD","LU1429558221.USD","LU0215105999.USD","LU0098860793.USD","LU0949170772.SGD","LU0648000940.SGD","LU0289739699.SGD","LU0054578231.USD","LU1162221912.USD","LU2237957811.SGD","BK4516","SUNB","LU1941712348.USD","LU0130103400.USD","BK4104","ERX","LU1116320901.HKD","LU0266512473.USD","LTL","LU0266013472.USD","LU1791710400.SGD","VTRS","LU0784383803.USD","IE0001KFT4U8.USD","SG9999014898.SGD","IE00BQXX3F31.USD","LU1064131342.USD","SGXZ81514606.USD","LU0820561909.HKD","LU2125154935.USD","IE00BGHQF524.EUR","LU2461242641.AUD","LU0170899867.USD","LU1935042991.SGD","IXC","LU2999663052.SGD","LU0788109394.HKD","LU0267386448.USD","LU1267930227.SGD","IE00BN29S564.USD","LU0097036916.USD","LU1069347547.HKD","LU2552382058.USD","LU0314106906.USD","IE000MB6IJN5.SGD","BK4547","IE00B5949003.HKD","LU0109392836.USD","LU1868837300.USD","XLE","LU0444971666.USD","IE00BK4W5M84.HKD","BK4539","IE00B19Z8W00.USD","IE00BKDWB100.SGD","LU1582986433.USD","LU1629891620.HKD","IE000M9KFDE8.USD","IE00BJTD4N35.SGD","BK4566","LU0068578508.USD","LU1720051108.HKD","LU2361045086.USD","XOMZ","LU2361044949.HKD","LU0052756011.USD","LU1435385759.SGD","LU1564329628.SGD","LU1201861165.SGD","LU2463028550.USD","LU2322448957.HKD","LU0784384876.USD","LU0672654240.SGD","LU0072461881.USD","LU1242518857.USD","LU1169590202.USD","LU1718418525.SGD","LU2404859667.USD","BPAY","LU1267930730.SGD","LU1894683264.USD","IE0009356076.USD","IE00B1XK9C88.USD","BK4142","SG9999015358.SGD","LU2087625088.SGD","LU0061474960.USD","LU0630314457.HKD","LU2756315318.SGD","LU1992135399.USD","IE000ITXATA3.USD","LU0528227936.USD","LU0154236417.USD","FCOM","LU1119994496.HKD","LU1642822529.SGD","IE0004445239.USD","LU0162691827.USD","LU0545039389.USD","LU1670711123.USD","LU2023250843.SGD","LU2236285917.USD","SGXZ99366536.SGD","LU0203202063.USD","LU2505996509.AUD","JILL","LU1059921491.USD","BK4094","LU2237957902.USD","XLC","IE00B19Z9505.USD","LU0784385170.HKD","LU1035773651.USD","SMETAmain","LU1430597077.USD","LU0130102774.USD","LU1670710661.SGD","LU0211326755.USD","LU0211331839.USD","METQ","LU1069344957.HKD","LU1868836914.USD","LU2129689514.USD","TRUC","LU0266512127.USD","LU0345781412.USD","LU0314104364.USD","LU1791710582.SGD","LU2458330243.SGD","BK4023","IE00BFSS7M15.SGD","LU2420271590.USD","LU2272731600.USD","LU0187121727.USD","LU1720051017.SGD","LU2471134952.CNY","LU2168564222.USD","LU2168564065.EUR","LU2168564149.EUR","SMMT","LU0225283273.USD","LU1582987324.SGD","LU2746668974.SGD","OGIG","LU0353189763.USD","LU0823434740.USD","LU1697837992.HKD","SG9999018865.SGD","LU2360107671.USD","BK4534","SG9999002232.USD","LU1929549753.HKD","LU0072462426.USD","LU1116320737.USD","LU0058720904.USD","FENY","LU0979878070.USD","LU0198837287.USD","LU0456854461.SGD","TEXU","LU1935042215.USD","WLK","LU0345770993.USD","LU2087621335.USD","LU2065171402.SGD","LU1496350502.SGD","CHYM","LU0345769631.USD","LU2054465674.USD","LU0011850046.USD","LU0106261372.USD","LU0345774631.USD","LU0276348264.USD","LU0708995401.HKD","LU2360032135.SGD","LU1699723380.USD","SOCL","XOM","BK4140","LU1674673428.USD","BK4535","LU0552385451.USD","IE00BSNM7G36.USD","LU0128525689.USD","SG9999014914.USD","LU2462611646.USD","IEO","LU0056508442.USD","XDAT","INGM","LU0784385840.USD","OXY","LU1823568750.SGD","BKNU","LU1868837136.USD","LU2592432038.USD","SFD","LU0823411888.USD","LU0868494708.USD","LU2168563687.JPY","LU0795875169.SGD","LU1804176565.USD","BK4139","LU2361044865.SGD","LU0320765646.SGD","LU2462591350.SGD","IE00B7KXQ091.USD","WEEI","LU2264538146.SGD","LU0143551892.USD","LU0203201768.USD","HK0000914686.HKD","LU1582986359.USD","LU2552382132.HKD","METV","LU0208291251.USD","LU0868494617.USD","IE00B1BXHZ80.USD","LU0203345920.USD","IE0004445015.USD","LU0477156797.USD","OILT","SGXZ51526630.SGD","LU1861558580.USD","SG9999001440.SGD","LU0823421416.USD","LU0557290698.USD","METG","IGE","LU2242650005.HKD","LU1989764664.SGD","AWAY","BK4585","LU1670627923.USD","SG9999004303.SGD","LU0234572021.USD","LU0210536198.USD","LU0320765489.SGD","LU2543165471.USD","LU2417539215.USD","LU0820561818.USD","LU1861559042.SGD","LU1153585028.USD","LU0788109477.HKD","LU0310800379.SGD","VOX","LU0477156953.USD","LU0354030438.USD","SG9999001077.SGD","IE0005OL40V9.USD","IE00B4YYXB79.USD","LU1066051498.USD","IE0000B7K699.USD","SG9999015952.SGD","LU1815333072.USD","LU0786609619.USD","BK4583","LU1914381329.SGD","LU0211328371.USD","BK4561","LU0053666078.USD","LU1894683348.USD","LU2133065610.SGD","LU0316494557.USD","LU0787776722.HKD","SG9999014575.USD","LU0689472784.USD","LU1992135472.HKD","LU2750360997.AUD","IE00BFSS8Q28.SGD","LU1506573853.SGD","SG9999018857.SGD","LU0256863811.USD","SG9999014542.SGD","LU1084165304.USD","CVX","IE00BZ1G4Q59.USD","LU2471134796.USD","LU1670628061.USD","IRT","GXPC","LU0878866978.SGD","IE00B7SZLL34.SGD","LU0300736062.USD","LU1564329032.USD","XOMX","NULC","BK4215","LU0061475181.USD","LU1582987597.SGD","LU0726765562.USD","WNDR","IE000SO60NU8.SGD","LU0553294199.USD","LU2247934214.USD","FBL","IE00B19Z3B42.SGD","LU0238689110.USD","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","BK4112","LU0889566641.SGD","LU0265550359.USD","CHWY","LU2357305700.SGD","LU2764262908.HKD","SG9999017495.SGD","LU1267930490.SGD","GAMR","LU0690374961.EUR","LU2750360641.GBP","LU1316542783.SGD","BK4524","LU2430703095.HKD","CGNT","LU0157215616.USD","LU1670711040.USD","IYE","IE00BJTD4V19.USD","IE00B4JS1V06.HKD","IE000WAW04H5.SGD","LU2602419157.SGD","LU2381873111.SGD","IE0002270589.USD","LU2764263203.CNY","DRLL","LU0882574139.USD","BK4201","GXPE","LU0256863902.USD","IE00B5TLWC47.USD","LU0149725797.USD","LU0417517546.SGD","LU1883866441.USD","LU1935043536.SGD","LU0823434583.USD","LU2430703178.SGD","LU0642271901.SGD","BKKT","GB00B4QBRK32.GBP","LU1988902786.USD","LU2065169927.USD","IE000F7OJYX1.SGD","LU0070217475.USD","LU1150488135.SGD","LU0278409577.USD","LU2265009873.SGD","LU1732800096.USD","XOMO","FXG","IE00BFXG1179.USD","LU0426417589.USD","SG9999015978.USD","LU0310799852.SGD","FCG","IE000YTNTUN2.SGD","LU1852331112.SGD","LU1267930813.SGD","LU0719512351.SGD","LU1145028129.USD","LU0496365809.HKD","LU0724617625.USD","SG9999015945.SGD","LU0308772762.SGD","LU0061474705.USD","LU0949170426.SGD","LU1430594728.SGD","GB00BDT5M118.USD","LU0310800965.SGD","PAWZ","SG9999014567.USD","LU2129689431.USD","LU0323591593.USD","METU","LU0203347892.USD","LU1941712264.USD","LU2250418816.HKD","LU0690374615.EUR","LU0079474960.USD","LU0128525929.USD","LU0096362180.USD","LU0648001328.SGD","LU1127390331.HKD","IE0034235188.USD","LU1674673691.USD","LU0082616367.USD","LU1935043023.USD","LU2272731865.HKD","SGXZ23171101.USD","LU0820562030.AUD","BK4007","LU0994945656.USD","LU1235294995.USD","LU0612318385.USD","BK4213","CI","LU0077335932.USD","LU2473716301.USD","LU2347655156.SGD","LU1032466523.USD","LU2360106780.USD","LU1242518931.SGD","LU2244417387.USD","SG9999015341.SGD","DIG","LU0683600562.USD","LU2462591277.SGD","LU1814569148.SGD","IE00BWXC8680.SGD","LU1564329461.SGD","IE00B19Z8X17.USD","LU0006306889.USD","LU2106854487.HKD","LU2322448791.USD","LU0912757837.SGD","LU1571399168.USD","BK4550","LU2102340556.USD","LU0612318971.USD","LU1035775433.USD","BK4090","LU1366333091.USD","LU0964807845.USD","LU2860962120.EUR","LU0661504455.SGD","LU2471134879.HKD","LU2498475776.HKD","IE00BQXX3D17.EUR","BK4077","LU2237438978.USD","LU0320765059.SGD","LU1066053197.SGD","IE00BJJMRY28.SGD","LU0070302665.USD","LU0109391861.USD","BK4548","GB00B4LPDJ14.GBP","LU0210528500.USD","LU0426412945.USD","LU2065170008.USD","LU0976567544.SGD","LU1935043452.HKD","TRUN","IE000W1ABFV2.USD","LU0466842654.USD","FBX","LU2063271972.USD","LU1169589451.USD","LU2347655073.USD","LU0433182093.SGD","LU2213496289.HKD","IE00BMPRXR70.SGD","LU1201861249.SGD","LU0985320562.USD","LU0980610538.SGD","TYRA","HK0000304805.HKD","LU0889565833.HKD","BK4570","BK4196","VDE","LU1815336760.USD","BK4588","BK4507","RSPC","LU1585245621.USD","BK4587","LU0345769128.USD","LU0640476718.USD","LU0654597011.USD","LU2168564495.EUR","LU1150488218.USD","LU0738911758.USD","TH","SGXZ80539844.SGD","LU2954938101.SGD","BK4197","BK4227","LU0985489474.SGD","LU1043141396.HKD","LU2505996681.GBP","LU2756315664.SGD","LU1074936037.SGD","LU1366192091.USD","LU2552382215.SGD","LU0122376428.USD","IE00BQXX3C00.GBP","IE00BK4W5L77.USD","LU1861217088.USD","LU1974910355.USD","LU0708994859.HKD","BK4581","IE0034235303.USD","LU2430703251.USD","BK4200","LU2764263039.SGD","LU1839511570.USD","LU2125154778.USD","LU1935042488.USD","UGI","LU1489326972.SGD","LU2023250330.USD","IE00B3SWFQ91.USD","IE00B775H168.HKD","SGXZ31699556.SGD","LU1551013342.USD","LU0234570918.USD","LU2487616109.SGD","SG9999014880.SGD","FTXN","LU1670710588.SGD","BK4595","LU1778281490.HKD","LU2065171311.SGD","LU1979441026.SGD","LU2896262040.SGD","EVMN","BK4122","HK0000914660.USD","LU1003077747.HKD","FBYY","LU0476273544.USD","LU1232071149.USD","LU0942090050.USD","LU2471134523.USD","LU0859254822.USD","LU2456880835.USD","LU2488822045.USD","LU2458330169.SGD","LU1548497426.USD","BKNG","LU0348723411.USD","IE00BJLML261.HKD","LU1803068979.SGD","LU0300736492.USD","LU0130518102.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580430","title":"Compass Pathways Rises After One-Year Data for Psychedelic-Based Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580430","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580430?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:46","pubTimestamp":1788954365,"startTime":"0","endTime":"0","summary":"BUZZ-Compass Pathways rises after one-year data for psychedelic-based depression drug** Shares of Compass PathwaysCMPS.Orise 5.3% to $14.78 premarket** Co reports 52-week data from its late-stage trial showing that additional doses of its psychedelic-based treatment, COMP360, helped sustain reductions in depression symptoms in patients with treatment-resistant depression ** CMPS says patients who were initially assigned to the 25 mg COMP360 arm and received an additional dose in the open-label portion of the study showed an average 13-point reduction from baseline on a scale used to measure the severity of depressive episodes at week 52** Across all participants receiving a 25 mg dose during the open-label phase, response rates were 40%-45% and about 30% achieved remission during the six weeks after treatment** Compass says a rolling submission of its U.S. new drug application is underway, with final filing expected in Q4** It expects a potential commercial launch in H1 2027** As of la","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N4510ZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584065","title":"Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 Comp005 Trial Demonstrates Additional Benefit from Another Comp360 Dose in Part C Extending Durability Out to 1 Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584065?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584051","title":"Compass Pathways - Rolling Nda Submission Underway; Final Submission on Track for Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584051?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584015","title":"Compass Pathways - Continue to Expect Commercial Launch in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584015?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458406","title":"Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458406?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666054584","title":"Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2666054584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666054584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303585","title":"Aureka launches placement and share purchase plan to fund mine expansion and exploration","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303585","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303585?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:53","pubTimestamp":1788911605,"startTime":"0","endTime":"0","summary":"Aureka Limited ( ($AU:AKA) ) just unveiled an update. Aureka Limited has launched a capital raising initiative comprising a $5.65 million share pla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4122","AKA","PSIL","BK4094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","FHLC","IDNA","GDOC","AZNH","MEDX","SYNB","SURI","MNTL","TBXU","IEIH","BME","WDNA","GNMX","LLYX","PBE","HRTS","SBIO","NVIB","FBT","LFSC","PJP","MEDI","FTXH","MDTX","APXH","GNOM","IBRN","GSKH","BBP","XPH","PTH","RSPH","CURE","FXH","JDOC","JHMH","IBBQ","PINK","PSIL","IBBJ","IBB","MRNY","PBPH","BBH","HYLG","PSCH","BIB","CANC","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","SBIO","GSKH","FHLC","IBBQ","BME","MDTX","RSPH","LLYX","CNCR","CURE","PBE","PJP","JDOC","IBBJ","BIB","CANC","LFSC","SYNB","FTXH","JHMH","PTH","IBRN","BBH","GPCR","TBXU","WDNA","PBPH","NVIB","HYLG","PSCH","SURI","PSIL","IBB","MEDI","BBP","FBT","PINK","FXH","MEDX","MNTL","HRTS","XPH","AZNH","GNMX","APXH","LENZ","GDOC","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665037847","title":"BioAge Labs doses first patient in QUELL-DME study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665037847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665037847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:35","pubTimestamp":1788870924,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665676320","title":"Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665676320","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665676320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869106,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics says CMO-Urology Raj S. Pruthi departsRelmada Therapeutics’ Chief Medical Officer – Urology, Raj S. Pruthi, left the company on Sept. 3, 2026.Disclaimer:This news brief was create","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL6M2JyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327821","title":"Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327821","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327821?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:11","pubTimestamp":1788865885,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel in adult patients w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU1883839398.USD","IE0009355771.USD","LU1670710661.SGD","LU0267386448.USD","BMY","LU0321505868.SGD","LU1291159041.SGD","LU1236620834.HKD","BK4126","LU1074936037.SGD","LU1430594728.SGD","LU1670711123.USD","LU1983299246.USD","LU0985481810.HKD","BBC","LU0456855351.SGD","LU2360032135.SGD","LU0868494617.USD","LU0432979614.USD","LU2596442595.SGD","LU1261432733.SGD","LU1032466523.USD","LU0114720955.EUR","BK4559","BK4588","LU2242652126.USD","LU0882574055.USD","LU1236620750.USD","LU2125154935.USD","IHE","LU1989771016.USD","FTXH","IE00BSNM7G36.USD","LU1093756168.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","PSIL","LU0237698245.USD","LU0061475181.USD","BK4534","BK4585","LU0225284248.USD","LU1093756325.SGD","LU2133065610.SGD","LU1718418525.SGD","MYE","LU1670710588.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322488","title":"NRx Pharma to Present at Moody Capital Solutions Disruptive Growth & Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322488","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322488?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:06","pubTimestamp":1788865578,"startTime":"0","endTime":"0","summary":"NRx Pharma to present at Moody Capital Solutions Disruptive Growth & Life Sciences ConferenceNRx Pharmaceuticals management will present at investor conferences in New York on Sept. 9, Sept. 11, Sept.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1TRKCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","CFSU","SG9999014005.SGD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","NRXP","BK4112","LU0314104364.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","BCDF","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","PSIL","SG9999014039.USD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","IE00BQXX3F31.USD","BK4588","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665138360","title":"FBR raises A$4m to accelerate DST-powered robotics rollout","url":"https://stock-news.laohu8.com/highlight/detail?id=2665138360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665138360?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:51","pubTimestamp":1788738718,"startTime":"0","endTime":"0","summary":"The latest announcement is out from FBR Limited ( ($AU:FBR) ). FBR Limited has launched a A$4 million capital raising comprising a A$1.5 million sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fbr-raises-a4m-to-accelerate-dst-powered-robotics-rollout?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fbr-raises-a4m-to-accelerate-dst-powered-robotics-rollout?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","DARP","DYNI","KOMP","PBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ADHD","MEDX","IBRN","ALKS","PSCH","FBT","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386764","title":"Right Resources shareholders back director placements and capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386764","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386764?lang=en_us&edition=fundamental","pubTime":"2026-09-04 12:17","pubTimestamp":1788495451,"startTime":"0","endTime":"0","summary":"Right Resources Limited ( ($AU:RRE) ) has shared an announcement. Right Resources Limited has reported that all resolutions put to shareholders at ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/right-resources-shareholders-back-director-placements-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/right-resources-shareholders-back-director-placements-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MEDX","PSIL","PSCH","BK4139","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664014408","title":"Compass Pathways Grants Inducement Equity Awards Covering 414,100 Shares to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2664014408","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664014408?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:30","pubTimestamp":1788467422,"startTime":"0","endTime":"0","summary":"Compass Pathways grants inducement equity awards covering 414,100 shares to new hiresCompass Pathways granted inducement equity awards on Sept. 1, 2026 to 31 newly hired non-executive employees.Option","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1B01xs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}